Tadalafil Tablet
Product Images NDC 71335-2363

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71335-2363). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

Chemical structure of tadalafil, the active ingredient in the drug TADALAFIL. The diagram shows the molecular arrangement and bonds characteristic of this compound.*

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

A four-panel chart showing the difference in blood pressure measurements (tadalafil minus placebo, in mmHg) over time (up to 96 hours). Panels depict standing systolic and diastolic blood pressure (BP) and supine systolic and diastolic BP. Each graph plots time on the x-axis and BP difference on the y-axis, illustrating trends with error bars.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

A two-panel line graph depicting changes in systolic blood pressure (mmHg) over 24 hours post-dose. The top panel shows standing systolic blood pressure and the bottom panel shows supine systolic blood pressure. Both compare Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg, with time (hours) post-dose on the x-axis and change in blood pressure on the y-axis.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

A line graph showing systolic blood pressure (mmHg) over time after administration of tadalafil or placebo. It compares four groups: 20 mg tadalafil administered at 08:00 with 8 mg doxazosin, placebo at 08:00 with 8 mg doxazosin, 20 mg tadalafil administered at 20:00 with 8 mg doxazosin, and placebo at 20:00 with 8 mg doxazosin. The x-axis is time in hours post-dose, and the y-axis shows changes in systolic blood pressure.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three conditions: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose after 5 consecutive days. The graph displays concentration decay over 120 hours with error bars indicating variability at each time point.*

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

A line graph comparing change from baseline in IPSS total score over 12 weeks of treatment. The graph shows two lines: one for tadalafil tablets 5 mg and one for placebo. The vertical axis represents the change in IPSS total score, ranging from 0 to -6, and the horizontal axis represents the duration of treatment in weeks (0, 4, 8, 12). Tadalafil shows a greater reduction in score over time compared to placebo, with a statistically significant difference indicated at 12 weeks.*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

A line graph showing the change from baseline in IPSS total score over 12 weeks of treatment comparing Tadalafil 5 mg tablets and placebo. The graph plots treatment duration on the x-axis and score change on the y-axis, with Tadalafil demonstrating greater improvement than placebo at multiple time points, with statistical significance indicated at week 4.*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

A line graph showing weeks of therapy on the horizontal axis (0, 4, 12, 26) and least squares mean change from baseline on the vertical axis (-7.0 to 0.0). It compares Tadalafil/Finasteride and Placebo/Finasteride groups, with markers and trend lines for each. The graph includes data points with differences labeled and notes significance levels (p<0.001, p<0.05).*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

A line graph showing the change from baseline in IPSS total score over a 12-week treatment period, comparing tadalafil tablets 5 mg and placebo. The x-axis represents duration of treatment in weeks, and the y-axis shows change in score. The graph indicates a greater decrease in IPSS score with tadalafil than placebo, with statistical significance noted at 12 weeks.*

FDA Label Image

Label (Lbl713352363)

Label for Tadalafil Tablets, USP 2.5 mg, oral tablets. The label shows a package size of 90 tablets, repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd. Instructions include storing at 25°C with permitted excursions, keeping out of reach of children, and dispensing in a tight container.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.